What two primary barriers are identified as crucial factors hindering the widespread scaling and equitable access of PGx testing?
Answer
Reimbursement and education.
For pharmacogenomics to achieve its promise of precision medicine for everyone, it must overcome systemic obstacles that limit access, especially for vulnerable populations. The text highlights that if testing remains costly or restricted to specialized sites, it will inevitably widen existing health disparities. The two primary roadblocks preventing the necessary scale and broad adoption are financial and knowledge-based. Reimbursement policies from insurance payers must consistently recognize the value of actionable PGx tests, and education must advance among both clinicians (to apply results) and patients (to provide informed consent and adhere to treatment).
Related Questions
What is the fundamental aim of personalized medicine enabled by Pharmacogenomics (PGx)?What does the next wave of PGx advancement involve shifting away from in terms of testing methodology?What feature do Polygenic Risk Scores (PRS) aggregate to predict complex traits like drug response?How does the future vision of PGx testing redefine the timing of its application compared to current practices?What process is deemed crucial for embedding PGx insights directly into the electronic health record (EHR) and clinical workflow?What sophisticated capability should future Clinical Decision Support Systems (CDSS) possess regarding prescription writing?How is Artificial Intelligence (AI) and Machine Learning (ML) expected to improve drug response predictions beyond current rule-based systems?What two primary barriers are identified as crucial factors hindering the widespread scaling and equitable access of PGx testing?What specialized task will pharmacists perform by translating raw genotype data in the PGx pathway?What regulatory clarity is expected in the future regarding drug labels and PGx guidance from bodies like the FDA?